Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gansulin
- Development stage
- Unknown
- Lead developer
- Gan & Lee Pharmaceuticals
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous, Intravenous, Intramuscular
01
Overview
Gansulin is a brand of human insulin products marketed by Gan & Lee Pharmaceuticals, China's largest domestic insulin manufacturer. It encompasses various formulations, including short-acting human insulin (Gansulin R) and biphasic human insulin (Gansulin M30), which is a mixture of soluble and isophane insulin. These products are utilized in the management of diabetes by regulating glucose metabolism.
- Brand names
- Gansulin
- Other names
- Gensulin
02
Targets
INSR (Insulin receptor)IGF-1R (Insulin-like growth factor 1 receptor)
Beyond the preview
Go deeper on Gansulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gansulin.